Lorcaserin - University of California at San Fransisco/Epygenix Therapeutics

Drug Profile

Lorcaserin - University of California at San Fransisco/Epygenix Therapeutics

Alternative Names: EPX 200

Latest Information Update: 09 Jun 2017

Price : $50

At a glance

  • Originator University of California at San Francisco
  • Developer University of California at San Francisco; University of Colorado at Denver
  • Class Benzazepines; Obesity therapies; Small molecules
  • Mechanism of Action Serotonin 2C receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dravet syndrome
  • New Molecular Entity No
  • Available For Licensing Yes - Dravet syndrome

Highest Development Phases

  • Phase II Dravet syndrome

Most Recent Events

  • 03 May 2017 Phase-II clinical trials in Dravet syndrome in USA (unspecified route) (Epygenix Therapeutics pipeline, May 2017)
  • 03 May 2017 Chemical structure information added
  • 25 Apr 2017 Lorcaserin - University of California at San Fransisco/Epygenix Therapeutics receives Orphan Drug status for Dravet syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top